GlassScriptPhysician profile
Jason A Lauf
NPI 1043896830
$2,472.45
in general payments reported to CMS, 2019-2025
33 companies · $1,561 in 2025
The $1,561 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $21.76 · 2023: $16.07 · 2024: $874 · 2025: $1,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,450.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $533.53 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $433.25 | 2024-2025 | |
| Pfizer INC. | $260.11 | 2024-2025 | |
| Novo Nordisk INC | $115.39 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $109.88 | 2024 | Minimed 780g |
| Exact Sciences Corporation | $81.68 | 2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $80.66 | 2024-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $65.32 | 2024-2025 | Repatha, Otezla, Evenity |
| Alexion Pharmaceuticals, INC. | $62.12 | 2024-2025 | Strensiq |
| Astellas Pharma US INC | $59.93 | 2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.58 | 2024-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $49.49 | 2024 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.95 | 2025 | Caplyta |
| Tolmar, INC. | $46.36 | 2024-2025 | Jatenzo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.79 | 2024-2025 | Xifaxan |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $42.27 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $40.93 | 2024 | Camzyos, Eliquis |
| Corcept Therapeutics | $39.55 | 2024-2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $33.38 | 2024-2025 | Trintellix |
| Cequr Corporation | $29.44 | 2024 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $24.43 | 2025 | Capvaxive |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.26 | 2025 | Rejoyn |
| Actelion Pharmaceuticals US, INC. | $22.57 | 2025 | Opsumit, Uptravi |
| Lundbeck LLC | $21.82 | 2025 | Vyepti |
| Seqirus USA INC | $20.29 | 2025 | Flucelvax, Fluad |
| Novartis Pharmaceuticals Corporation | $18.76 | 2024 | |
| Vivaquant INC, Dba Rhythm Express | $17.85 | 2025 | Rhythm Express |
| Hologic Sales and Service, LLC | $17.32 | 2025 | Thinprep 2000 Processor, Aptima |
| Lilly USA, LLC | $16.70 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $16.52 | 2024 | |
| Abbott Laboratories | $16.15 | 2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $14.09 | 2025 | Auvelity |
| Echosens North America, INC. | $12.08 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Lauf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.